Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer.

@article{Rosell2010EpidermalGF,
  title={Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer.},
  author={Rafael Rosell and Santiago Viteri and Miguel {\'A}ngel Molina and Susana Benlloch and M{\`i}quel Taron},
  journal={Current opinion in oncology},
  year={2010},
  volume={22 2},
  pages={112-20}
}
PURPOSE OF REVIEW Classic activating mutations in the form of deletions in exon 19 or a missense mutation L858R in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) predict dramatic responses to EGFR tyrosine kinase inhibitors such as gefitinib and erlotinib. We review here the clinical benefits of targeted therapy with erlotinib and gefitinib in white and Asian nonsmall-cell lung cancer patients. RECENT FINDINGS Two separate analyses of pooled data from small phase II… CONTINUE READING
14 Citations
43 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 43 references

Cancer . Complicated supercomplexes

  • PC Fong, DS Boss, TA Yap
  • Science
  • 2009

Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV nonsmall - cell lung cancer

  • L Mao, HS Wang
  • J Clin Oncol
  • 2009

Similar Papers

Loading similar papers…